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The authors reply: As stated in our conclusion, 
the overall survival benefit was observed in the 
entire population receiving ADT and docetaxel. 
This benefit at the early analysis appears to be 
driven primarily by men with high-volume dis-
ease. Although definitions intended to character-
ize disease volume have limitations, two other 
phase 3 trials have yielded similar findings on 
overall survival when our definitions of disease 
volume were applied.1,2 It is also clear that pros-
tate cancer is a heterogeneous disease, and we 
agree that the development of molecular bio-
markers is very important. To this end, we agree 
that biologic characterization of patients and 
their tumors, including quality-of-life data, could 
be of value.
With longer follow-up, the potential benefit of 
up-front chemotherapy for men with low-volume 
disease will be better defined. At this time, pa-
tient preference and physician judgment should 
determine who (including those with low-vol-
ume disease) receives chemotherapy. However, 
in a disease with a longer natural history, deaths 
not related to prostate cancer could affect overall 
survival. At this stage, there are no data to sup-
port the use of progression-free survival as a 
surrogate end point for overall survival.
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Cleveland Clinic 
Cleveland, OH
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Cryopreservation of Oocytes
To the Editor: In his review on cryopreserva-
tion of oocytes (Oct. 29 issue),1 Schattman rec-
ommends that “the possibility of elective cryo-
preservation of oocytes should be discussed with 
all women who are in their early 30s.” We ques-
tion this assertion. Although age-related infertil-
ity is of concern to many women, the evidence 
for successful pregnancy outcomes associated 
with elective oocyte cryopreservation is still lim-
ited, and the procedure carries potential risks for 
healthy women. The American Society for Repro-
ductive Medicine no longer considers this proce-
dure “experimental,” but it also recognizes the 
paucity of evidence with respect to safety, effi-
cacy, ethics, emotional risks, and cost-effective-
ness of oocyte cryopreservation for nonmedical 
indications.2 Elective cryopreservation is expen-
sive, and there is currently little objective and 
independent information to guide individual 
decision making. Discussions about oocyte cryo-
preservation usually take place with service pro-
viders who stand to gain a direct financial benefit. 
We are concerned that this universal clinical rec-
ommendation may fuel women’s anxiety about 
age-related infertility and promote the commercial 
business of oocyte cryopreservation, without as-
sisting clinicians in providing advice for women 
who are making complex decisions that affect 
their reproductive choices.
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To the Editor: With regard to a woman concerned 
about her future fertility, Schattman describes 
in detail the indications for cryopreservation of 
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oocytes, the process of cryopreservation, and the 
outcome for the preserved oocytes. He also ad-
vises that women who opt for this procedure 
should be counseled about the increased risks of 
pregnancy among older women, the immediate 
risk of the ovarian hyperstimulation syndrome, 
and “the potentially harmful effects on their fu-
ture fertility.” Unfortunately, he does not mention 
any other potential long-term health risks among 
women who undergo ovarian stimulation. Popu-
lation studies have suggested that there is an 
increased risk of various malignant conditions 
among women who undergo ovarian stimulation 
because of infertility or because they are con-
cerned about their future fertility.1 For another 
group of young women — those who undergo 
ovarian stimulation to donate or sell their ova 
— data on the potential long-term medical risks 
are lacking.2 In the United States, these women 
are predominantly anonymous donors, and reg-
istries that would enable studies of the potential 
long-term risks of this procedure are not main-
tained. All women who undergo ovarian stimula-
tion, especially more than once, should be told 
that their long-term health risks are unknown.
Jennifer P. Schneider, M.D., Ph.D.
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jennifer@ jenniferschneider . com
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The author replies: As clearly pointed out by 
Hickey et al., age-related infertility is a great con-
cern to many women. I agree that the recommen-
dation that “elective cryopreservation of oocytes 
should be discussed with all women who are in 
their early 30s” might have been better phrased 
to make clear that the effects of aging on repro-
duction should be discussed with all women 
when they are in their early 20s and 30s and that 
the option of oocyte cryopreservation can be of-
fered to women who are considering delaying 
childbearing until later in their reproductive years. 
The comment by Hickey et al. regarding the ex-
pense of oocyte cryopreservation does not take 
into account the costs in the longer term; oocyte 
cryopreservation at 35 years of age has been 
shown to result in a 48% greater probability of 
having a live birth than the probability associat-
ed with waiting until 40 years of age to attempt 
to conceive, as well as with a 27% lower cost per 
live birth.1
Although Schneider states as a fact that there 
is an increased risk of various malignant condi-
tions among women who undergo ovarian stim-
ulation and specifically refers to an unfortunate 
case of fatal colon cancer in a woman who previ-
ously donated oocytes, such findings cannot 
prove cause and effect. Women with infertility 
have a higher baseline risk of specific cancers 
even without exposure to ovarian stimulation.2 
A recent meta-analysis of data from 182,972 
women who were exposed to ovarian stimula-
tion showed “no convincing evidence of an in-
crease in the risk of invasive ovarian tumors 
with fertility drug treatment.”3 Further evidence 
from a study that linked data from an assisted 
reproductive technology database to state cancer 
registries also showed that women treated with 
assisted reproductive technology had an overall 
lower incidence of all cancers than women who 
were never treated with assisted reproductive 
technology (standardized incidence ratio, 0.78; 
95% confidence interval, 0.73 to 0.83).4 These 
observations may provide reassurance to women 
who desire to preserve their future fertility about 
the long-term safety of undergoing one or two 
cycles of treatment.
Glenn L. Schattman, M.D.
Weill Cornell Medical College 
New York, NY 
glschatt@ med . cornell . edu
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